High resolution micro-SPECT scanning in rats using 125I β-CIT: Effects of chronic treatment with carbamazepine
Stuart M. Cain
Epilepsy Unit, Division of Cardiovascular & Medical Sciences, University of Glasgow, Glasgow, United Kingdom
Division of Clinical Neuroscience, Wellcome Surgical Institute and 7T MRI Facility, University of Glasgow, Glasgow, United Kingdom
Present address: Dr Stuart M. Cain, Michael Smith Laboratories, 2185 East Mall, University of British Columbia, Vancouver, British Columbia, Canada
Search for more papers by this authorTorsten Ruest
Division of Clinical Neuroscience, Wellcome Surgical Institute and 7T MRI Facility, University of Glasgow, Glasgow, United Kingdom
Search for more papers by this authorSally Pimlott
Department of Clinical Physics, Southern General Hospital, Glasgow, United Kingdom
Search for more papers by this authorJim Patterson
Department of Clinical Physics, Southern General Hospital, Glasgow, United Kingdom
Search for more papers by this authorRod Duncan
Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom
Search for more papers by this authorDebbie Dewar
Division of Clinical Neuroscience, Wellcome Surgical Institute and 7T MRI Facility, University of Glasgow, Glasgow, United Kingdom
Search for more papers by this authorGraeme J. Sills
Epilepsy Unit, Division of Cardiovascular & Medical Sciences, University of Glasgow, Glasgow, United Kingdom
Present address: Dr Graeme J. Sills, University Division of Neurological Science, Clinical Sciences Centre, University Hospital Aintree, Liverpool L9 7AL, U.K.
Search for more papers by this authorStuart M. Cain
Epilepsy Unit, Division of Cardiovascular & Medical Sciences, University of Glasgow, Glasgow, United Kingdom
Division of Clinical Neuroscience, Wellcome Surgical Institute and 7T MRI Facility, University of Glasgow, Glasgow, United Kingdom
Present address: Dr Stuart M. Cain, Michael Smith Laboratories, 2185 East Mall, University of British Columbia, Vancouver, British Columbia, Canada
Search for more papers by this authorTorsten Ruest
Division of Clinical Neuroscience, Wellcome Surgical Institute and 7T MRI Facility, University of Glasgow, Glasgow, United Kingdom
Search for more papers by this authorSally Pimlott
Department of Clinical Physics, Southern General Hospital, Glasgow, United Kingdom
Search for more papers by this authorJim Patterson
Department of Clinical Physics, Southern General Hospital, Glasgow, United Kingdom
Search for more papers by this authorRod Duncan
Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom
Search for more papers by this authorDebbie Dewar
Division of Clinical Neuroscience, Wellcome Surgical Institute and 7T MRI Facility, University of Glasgow, Glasgow, United Kingdom
Search for more papers by this authorGraeme J. Sills
Epilepsy Unit, Division of Cardiovascular & Medical Sciences, University of Glasgow, Glasgow, United Kingdom
Present address: Dr Graeme J. Sills, University Division of Neurological Science, Clinical Sciences Centre, University Hospital Aintree, Liverpool L9 7AL, U.K.
Search for more papers by this authorSummary
Purpose: Carbamazepine (CBZ) is a first-line antiepileptic agent with mood-stabilizing effects in bipolar disorder. It has been reported to influence extracellular concentrations of serotonin and dopamine, suggesting an interaction with monoamine transporters. We have investigated this effect using in vivo single photon emission computed tomography (SPECT) in rats.
Methods: Adult male rats received 3 mg/kg/h CBZ via mini-osmotic pump. After 14 days continuous treatment, animals underwent two consecutive SPECT scans, using 125I β-CIT as a radiotracer to label serotonin transporter (SERT) and dopamine transporter (DAT) sites in the brain. Pharmacologic distinction was enabled by 125I β-CIT SPECT imaging in rats acutely exposed to the serotonin and dopamine transporter inhibitors, fluoxetine and GBR12909. The interaction between CBZ and 125I β-CIT binding to SERT and DAT was investigated using in vitro autoradiography.
Results: Carbamazepine (10 μm) did not affect binding of 125I β-CIT to isolated rat brain slices, thereby excluding a direct effect on ligand binding to SERT and DAT. SPECT studies with fluoxetine and GBR12909 highlighted SERT binding in thalamus, hippocampus, centromedial nuclei, and occipital cortex, and DAT binding in the caudate. Prolonged treatment with CBZ failed to influence 125I β-CIT binding to either SERT or DAT in any of the brain regions examined.
Discussion: This study employed the novel technique of small animal SPECT imaging to investigate the effects of CBZ on monoamine transporters in rat brain. Following prolonged treatment, the drug was without effect on SERT or DAT availability. The mechanism by which CBZ exerts its mood stabilizing effects remains elusive.
References
- Ahmad S, Fowler LJ, Whitton PS. (2005) Lamotrigine, carbamazepine and phenytoin differentially alter extracellular levels of 5-hydroxytryptamine, dopamine and amino acids. Epilepsy Res 63: 141–149.
- Bagdy G, Kecskemeti V, Riba P, Jakus R. (2007) Serotonin and epilepsy. J Neurochem 100: 857–873.
- Baldwin RM, Zea-Ponce Y, Zoghbi SS, Laurelle M, Al Tikriti MS, Sybirska EH, Malison RT, Neumeyer JL, Milius RA, Wang S, Stabin M, Smith EO, Charney DS, Hoffer PB, Innis RB. (1993) Evaluation of the monoamine uptake site ligand [123I]methyl 3 beta-(4-iodophenyl)-tropane-2 beta-carboxylate ([123I]beta-CIT) in non-human primates: pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI. Nucl Med Biol 20: 597–606.
- Bazil CW, Pedley TA. (2003) Clinical pharmacology of antiepileptic drugs. Clin Neuropharmacol 26: 38–52.
- Booij J, De Jong J, De Bruin K, Knol R, De Win MM, Van Eck-Smit BL. (2007) Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. J Nucl Med 48: 359–366.
- Brodie MJ, Dichter MA. (1996) Antiepileptic drugs. N Engl J Med 334: 168–175.
- Courtney KR, Etter EF. (1983) Modulated anticonvulsant block of sodium channels in nerve and muscle. Eur J Pharmacol 88: 1–9.
- Dailey JW, Yan QS, Adams-Curtis L, Ryu JR, Ko KH, Mishra PK, Jobe PC. (1996) Neurochemical correlates of antiepileptic drugs in the genetically epilepsy-prone rat (GEPR). Life Sci 58: 259–266.
- Dailey JW, Reith ME, Yan QS, Li MY, Jobe PC. (1997a) Anticonvulsant doses of carbamazepine increase hippocampal extracellular serotonin in genetically epilepsy-prone rats: dose response relationships. Neurosci Lett 227: 13–16.
- Dailey JW, Reith ME, Yan QS, Li MY, Jobe PC. (1997b) Carbamazepine increases extracellular serotonin concentration: lack of antagonism by tetrodotoxin or zero Ca2+. Eur J Pharmacol 328: 153–162.
- Dailey JW, Reith ME, Steidley KR, Milbrandt JC, Jobe PC. (1998) Carbamazepine-induced release of serotonin from rat hippocampus in vitro. Epilepsia 39: 1054–1063.
- De Win MM, Habraken JB, Reneman L, Van Den Brink W, Den Heeten GJ, Booij J. (2005) Validation of [123I] β-CIT SPECT to assess serotonin transporters in vivo in humans: a double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram. Neuropsychopharmacology 30: 996–1005.
- Doheny HC, Whittington MA, Jefferys JGR, Patsalos PN. (2002) A comparison of the efficacy of carbamazepine and the novel antiepileptic drug levetiracetam in the tetanus toxin model of focal complex partial epilepsy. Br J Pharmacol 135: 1425–1434.
- Fujita M, Shimada S, Fukuchi K, Tohyama M, Nishimura T. (1994) Distribution of cocaine recognition sites in rat brain: in vitro and ex vivo autoradiography with [125I]RTI-55. J Chem Neuroanat 7: 13–23.
- Fujita M, Takatoku K, Matoba Y, Nishiura M, Kobayashi K, Inoue O, Nishimura T. (1996) Differential kinetics of [123I]beta-CIT binding to dopamine and serotonin transporters. Eur J Nucl Med 23: 431–436.
- Garcia-Cabezas MA, Rico B, Sanchez-Gonzalez MA, Cavada C. (2007) Distribution of the dopamine innervation in the macaque and human thalamus. Neuroimage 34: 965–984.
- Gunther I, Hall H, Halldin C, Swahn CG, Farde L, Sedvall G. (1997) [125I] beta-CIT-FE and [125I] beta-CIT-FP are superior to [125I] beta-CIT for dopamine transporter visualization: autoradiographic evaluation in the human brain. Nucl Med Biol 24: 629–634.
- Kanner AM, Balabanov A. (2002) Depression and epilepsy; how closely related are they? Neurology 58(suppl 5): S27–S39.
- Kawata Y, Okada M, Murakami T, Kamata A, Zhu G, Kaneko S. (2001) Pharmacological discrimination between effects of carbamazepine on hippocampal basal, Ca2+- and K+-evoked serotonin release. Br J Pharmacol 133: 557–567.
- Kugaya A, Seneca NM, Snyder PJ, Williams SA, Malison RT, Baldwin RM, Siebyl JP, Innis RB. (2003) Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology 28: 413–420.
- Kuikka JT, Tiihonen J, Bergstrom KA, Karhu J, Hartikainen P, Viinamaki H, Lansimies E, Lehtonen J, Hakola P. (1995) Imaging of serotonin and dopamine transporters in the living human brain. Eur J Nucl Med 22: 346–350.
- Laruelle M, Baldwin RM, Malison RT, Zea-Ponce Y, Zoghbi SS, Al-Tikriti MS, Sybirska EH, Zimmermann RC, Wisniewski G, Neumeyer JL. (1993) SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 13: 295–309.
- Mira SA, El-Sayed YM, Islam SI. (1987) Simultaneous measurement of phenobarbital, carbamazepine, phenytoin and 5-(4-hydroxyphenyl)-5-phenylhydantoin in serum by high-performance liquid chromatography. Analyst 112: 57–60.
- Okada M, Hirano T, Mizuno K, Kawata Y, Wada K, Murakami T, Tasaki H, Kaneko S. (1998a) Effects of carbamazepine on hippocampal serotonergic system. Epilepsy Res 31: 187–198.
- Okada T, Fujita M, Shimada S, Sato K, Schloss P, Watanabe Y, Itoh Y, Tohyama M, Nishimura T. (1998b) Assessment of affinities of beta-CIT, beta-CIT-FE, and beta-CIT-FP for monoamine transporters permanently expressed in cell lines. Nucl Med Biol 25: 53–58.
- Olivier B, Soudijn W, Van Wijngaarden I. (2000) Serotonin, dopamine and norepinephrine transporters in the central nervous system and their inhibitors. Arzneimittelforschung 54: 59–119.
- Oscarson M, Zanger UM, Rifki OF, Klein K, Eichelbaum M, Meyer UA. (2006) Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin Pharmacol Ther 80: 440–456.
- Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates. Academic Press, London.
- Peremans K, Goethals I, De Vos F, Dobbeleir A, Ham H, Van Bree H, Van Heeringen C, Audenaert K. (2006) Serotonin transporter and dopamine transporter imaging in the canine brain. Nucl Med Biol 33: 907–913.
- Sanchez-Gonzalez MA, Garcia-Cabezas MA, Rico B, Cavada C. (2005) The primate thalamus is a key target for brain dopamine. J Neurosci 25: 6076–6083.
- Sharma S, Ebadi M. (2008) SPECT neuroimaging in translational research of CNS disorders. Neurochem Int 52: 352–362.
- Stoddart HF, Stoddart HA. (1979) A new development in single-gamma transaxial tomography. Union carbide focused collimator scanner. IEEE Trans Nucl Sci 22: 726–731.
- Van Belle K, Sarre S, Ebinger G, Michotte Y. (1995) Brain, liver and blood distribution kinetics of carbamazepine and its metabolic interaction with clomipramine in rats: a quantitative microdialysis study. J Pharmacol Exp Ther 272: 1217–1222.
- Wang PW, Ketter TA. (2005) Clinical use of carbamazepine for bipolar disorders. Expert Opin Pharmacother 6: 2887–2902.
- Yan Q-S, Mishra PK, Burger RL, Bettendorf AF, Jobe PC, Dailey JW. (1992) Evidence that carbamazepine and antiepilepsirine may produce a component of their anticonvulsant effects by activating serotonergic neurons in genetically epilepsy-prone rats. J Pharmacol Exp Ther 261: 652–659.
Citing Literature
